Kaspar Berneis

Summary

Country: Switzerland

Publications

  1. ncbi Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?
    Manfredi Rizzo
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Via del Vespro 141, Palermo 90127, Italy
    J Atheroscler Thromb 12:237-9. 2005
  2. ncbi Combined stimulation of adrenocorticotropin and compound-S by single dose metyrapone test as an outpatient procedure to assess hypothalamic-pituitary-adrenal function
    K Berneis
    Division of Endocrinology, Diabetology and Clinical Nutrition, Department of Internal Medicine, University Hospitals, CH 4031 Basel, Switzerland
    J Clin Endocrinol Metab 87:5470-5. 2002
  3. ncbi LDL size: does it matter?
    K Berneis
    University Hospital Bruderholz, Department of Internal Medicine, Switzerland
    Swiss Med Wkly 134:720-4. 2004
  4. ncbi Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes
    Kaspar Berneis
    Department of Internal Medicine and Central Laboratories, Basel University Hospital Bruderholz, Switzerland 4101
    Metabolism 54:227-34. 2005
  5. pmc Moderate amounts of fructose consumption impair insulin sensitivity in healthy young men: a randomized controlled trial
    Isabelle Aeberli
    Division of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital Zurich, Zurich, Switzerland
    Diabetes Care 36:150-6. 2013
  6. pmc Small, dense LDL particles predict changes in intima media thickness and insulin resistance in men with type 2 diabetes and prediabetes--a prospective cohort study
    Philipp A Gerber
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital, Zurich, Zurich, Switzerland
    PLoS ONE 8:e72763. 2013
  7. ncbi Sugar-sweetened beverages with moderate amounts of fructose, but not sucrose, induce Fatty Acid synthesis in healthy young men: a randomized crossover study
    Michel Hochuli
    Division of Endocrinology, Diabetes, and Clinical Nutrition M Ho, i A, P A G, G A S, K B, University Hospital Zurich, 8091 Zurich, Switzerland Division of Clinical Chemistry and Biochemistry A W, M He, H T, University Children s Hospital Zurich, 8032 Zurich, Switzerland Human Nutrition Laboratory I A, Institute of Food, Nutrition, and Health and Competence Center for Systems Physiology and Metabolic Diseases P A G, G A S, ETH Zurich, 8092 Zurich, Switzerland Zurich Center for Integrative Human Physiology K B, 8057 Zurich, Switzerland
    J Clin Endocrinol Metab 99:2164-72. 2014
  8. ncbi Omega-3 fatty acids: role in metabolism and cardiovascular disease
    Philipp A Gerber
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Curr Pharm Des 19:3074-93. 2013
  9. doi Insulin sensitivity in type 2 diabetes is closely associated with LDL particle size
    Pierre A Krayenbuehl
    Department of Internal Medicine, Medical Policlinic, University Hospital Zurich, Zurich, Switzerland
    Swiss Med Wkly 138:275-80. 2008
  10. doi Low to moderate sugar-sweetened beverage consumption impairs glucose and lipid metabolism and promotes inflammation in healthy young men: a randomized controlled trial
    Isabelle Aeberli
    Division of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital Zurich, Zurich, Switzerland
    Am J Clin Nutr 94:479-85. 2011

Detail Information

Publications31

  1. ncbi Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?
    Manfredi Rizzo
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Via del Vespro 141, Palermo 90127, Italy
    J Atheroscler Thromb 12:237-9. 2005
    ....
  2. ncbi Combined stimulation of adrenocorticotropin and compound-S by single dose metyrapone test as an outpatient procedure to assess hypothalamic-pituitary-adrenal function
    K Berneis
    Division of Endocrinology, Diabetology and Clinical Nutrition, Department of Internal Medicine, University Hospitals, CH 4031 Basel, Switzerland
    J Clin Endocrinol Metab 87:5470-5. 2002
    ..Despite the relatively high cross-reactivity of CMP-S in the cortisol assay, the sum of CMP-S and cortisol levels with a cut-off value of 450 nmol/liter yields a better diagnostic accuracy compared with CMP-S alone...
  3. ncbi LDL size: does it matter?
    K Berneis
    University Hospital Bruderholz, Department of Internal Medicine, Switzerland
    Swiss Med Wkly 134:720-4. 2004
    ..The predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor by the adult treatment panel (ATP) III...
  4. ncbi Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes
    Kaspar Berneis
    Department of Internal Medicine and Central Laboratories, Basel University Hospital Bruderholz, Switzerland 4101
    Metabolism 54:227-34. 2005
    ..002) and IMT (P = .03). It is concluded that LDL size is the strongest marker for clinically apparent as well as non-apparent atherosclerosis in diabetes type 2...
  5. pmc Moderate amounts of fructose consumption impair insulin sensitivity in healthy young men: a randomized controlled trial
    Isabelle Aeberli
    Division of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital Zurich, Zurich, Switzerland
    Diabetes Care 36:150-6. 2013
    ..This study assessed the effect of moderate amounts of fructose and sucrose compared with glucose on glucose and lipid metabolism...
  6. pmc Small, dense LDL particles predict changes in intima media thickness and insulin resistance in men with type 2 diabetes and prediabetes--a prospective cohort study
    Philipp A Gerber
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital, Zurich, Zurich, Switzerland
    PLoS ONE 8:e72763. 2013
    ..Thus, this parameter extends the individual risk assessment beyond the limitations of traditional risk markers in patients with dysglycemia. ..
  7. ncbi Sugar-sweetened beverages with moderate amounts of fructose, but not sucrose, induce Fatty Acid synthesis in healthy young men: a randomized crossover study
    Michel Hochuli
    Division of Endocrinology, Diabetes, and Clinical Nutrition M Ho, i A, P A G, G A S, K B, University Hospital Zurich, 8091 Zurich, Switzerland Division of Clinical Chemistry and Biochemistry A W, M He, H T, University Children s Hospital Zurich, 8032 Zurich, Switzerland Human Nutrition Laboratory I A, Institute of Food, Nutrition, and Health and Competence Center for Systems Physiology and Metabolic Diseases P A G, G A S, ETH Zurich, 8092 Zurich, Switzerland Zurich Center for Integrative Human Physiology K B, 8057 Zurich, Switzerland
    J Clin Endocrinol Metab 99:2164-72. 2014
    ..The impact of sugar-sweetened beverages (SSB) on lipid metabolism when consumed in moderate amounts by normal weight subjects is debated...
  8. ncbi Omega-3 fatty acids: role in metabolism and cardiovascular disease
    Philipp A Gerber
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Curr Pharm Des 19:3074-93. 2013
    ....
  9. doi Insulin sensitivity in type 2 diabetes is closely associated with LDL particle size
    Pierre A Krayenbuehl
    Department of Internal Medicine, Medical Policlinic, University Hospital Zurich, Zurich, Switzerland
    Swiss Med Wkly 138:275-80. 2008
    ..Small dense LDLs have been found to be associated with type 2 diabetes (T2DM). This association has been observed in the context of decreased HDL cholesterol and increased triglycerides...
  10. doi Low to moderate sugar-sweetened beverage consumption impairs glucose and lipid metabolism and promotes inflammation in healthy young men: a randomized controlled trial
    Isabelle Aeberli
    Division of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital Zurich, Zurich, Switzerland
    Am J Clin Nutr 94:479-85. 2011
    ..Background: Sugar-sweetened beverages (SSBs) have unfavorable effects on glucose and lipid metabolism if consumed in high quantities by obese subjects, but the effect of lower doses in normal-weight subjects is less clear...
  11. doi Regulation of low-density lipoprotein subfractions by carbohydrates
    Philipp A Gerber
    Division of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital Zurich, Zurich, Switzerland
    Curr Opin Clin Nutr Metab Care 15:381-5. 2012
    ....
  12. doi Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial
    Kaspar Berneis
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Zurich and Zurich Center for Integrative Human Physiology, Zurich, Switzerland
    Eur Heart J 31:1633-9. 2010
    ..This study assessed by gradient gel electrophoresis the effects of ezetimibe alone, simvastatin alone, and their combination on sdLDL subfraction distribution...
  13. ncbi Disturbed eating at high altitude: influence of food preferences, acute mountain sickness and satiation hormones
    Isabelle Aeberli
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Zurich, Zurich, Switzerland
    Eur J Nutr 52:625-35. 2013
    ..The aim was therefore to assess changes in eating after rapid ascent to 4,559 m and to investigate to what extent hypoxia, acute mountain sickness (AMS), food preferences and satiation hormones influence eating behavior...
  14. doi The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis
    Kaspar Berneis
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Zurich, Switzerland
    Clin Chim Acta 406:36-40. 2009
    ..These three lipid abnormalities constitute the so-called "atherogenic-lipoprotein-phenotype" (ALP) but its predictive role in these patients still remains to be established...
  15. ncbi Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects
    Gabor Szinnai
    Division of Endocrinology, Diabetology, and Clinical Nutrition, University Hospital, CH 4031 Basel, Switzerland
    J Clin Endocrinol Metab 92:3973-8. 2007
    ..Copeptin is the C-terminal part of provasopressin and has been shown to be a useful tool to indicate AVP concentration in critically ill patients...
  16. ncbi Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes
    Kaspar Berneis
    University Hospital Zurich, Clinics for Endocrinology, Diabetes and Clinical Nutrition, Switzerland
    Expert Opin Pharmacother 9:343-9. 2008
    ..To assess the effects of pioglitazone and rosiglitazone on fasting and postprandial low-density lipoprotein (LDL) size and subclasses in patients with Type 2 diabetes...
  17. ncbi Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy
    Manfredi Rizzo
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Palermo, Italy
    Eur J Endocrinol 156:361-7. 2007
    ....
  18. ncbi Small, dense low-density-lipoproteins and the metabolic syndrome
    Manfredi Rizzo
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Italy
    Diabetes Metab Res Rev 23:14-20. 2007
    ..LDL size measurement may potentially help to assess cardiovascular risk within the metabolic syndrome and adapt the treatment goals thereafter...
  19. ncbi Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome
    Kaspar Berneis
    Clinic of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital, 8091 Zurich, Switzerland
    J Clin Endocrinol Metab 92:186-9. 2007
    ..In this study, we evaluated the presence of ALP in the plasma of women with PCOS...
  20. ncbi Should we measure routinely the LDL peak particle size?
    Manfredi Rizzo
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Italy
    Int J Cardiol 107:166-70. 2006
    ..Since the therapeutic modulation of small, dense LDL particles is of great benefit in reducing the atherosclerotic risk, the LDL size measurement should be extended to patients at high risk of coronary artery disease as much as possible...
  21. ncbi Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apoB in transgenic rabbits
    Manfredi Rizzo
    Department of Genome Sciences, Lawrence Berkeley National Laboratory, University of California, Berkeley, USA
    Arterioscler Thromb Vasc Biol 24:141-6. 2004
    ..The effects of combined expression of human hepatic lipase (HL) and human apolipoprotein B (apoB) on low-density lipoprotein (LDL) subclasses were examined in rabbits, a species naturally deficient in HL activity...
  22. ncbi The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?
    Manfredi Rizzo
    University of Palermo, Department of Internal Medicine and Emerging Diseases, Via del Vespro 141, 90127 Palermo, Italy
    Expert Opin Pharmacother 9:2295-303. 2008
    ....
  23. ncbi [Diabetes mellitus--diagnosis and blood glucose control]
    Barbara Elke
    Klinik und Poliklinik für Innere Medizin, Universitatsspital Zurich, Zurich
    Praxis (Bern 1994) 97:529-37; quiz 538-9. 2008
  24. ncbi Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter
    Kaspar Berneis
    Donner Laboratory, Lawrence Berkeley National Laboratory, University of California, Berkeley, CA, USA
    Metabolism 53:483-7. 2004
    ..This might be due to compositional or structural features of smaller LDL that lead to retarded clearance...
  25. ncbi The clinical relevance of low-density-lipoproteins size modulation by statins
    Manfredi Rizzo
    Dipartimento di Medicina Clinica e delle Patologie Emergenti, Universita di Palermo, Via del Vespro, 141, 90127 Palermo, Italy
    Cardiovasc Drugs Ther 20:205-17. 2006
    ..Finally, rosuvastatin, the latest statin molecule introduced in the market, seems to be promising in altering LDL subclasses towards less atherogenic particles...
  26. ncbi Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease
    Manfredi Rizzo
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Via del Vespro, 141, 90127 Palermo, Italy
    Atherosclerosis 197:237-41. 2008
    ..0024). ALP seems to characterize PAD dyslipidemia, but prospective studies are needed to test whether this lipoprotein phenotype may represent a risk factor too...
  27. ncbi The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates
    Manfredi Rizzo
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Italy
    Curr Med Res Opin 23:1103-11. 2007
    ..Fibrates have a major impact on triglyceride metabolism and in modulating LDL size and subclasses, but variations exist among the different molecules...
  28. ncbi Fructose intake is a predictor of LDL particle size in overweight schoolchildren
    Isabelle Aeberli
    Human Nutrition Laboratory, Institute of Food Science and Nutrition, ETH Zurich, Zurich, Switzerland
    Am J Clin Nutr 86:1174-8. 2007
    ..Childhood adiposity is associated with smaller LDL particle size, but the dietary predictors of LDL size in overweight children have not been studied...
  29. ncbi Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency
    Manfredi Rizzo
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Italy
    Growth Horm IGF Res 18:264-6. 2008
    ..In the present study we assessed post-prandial variations in LDL size and subclasses in patients with growth hormone deficiency (GHD)...
  30. ncbi An update on the role of the quality of LDL in cardiovascular risk: the contribution of the universities of Palermo and Zurich
    Manfredi Rizzo
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Palermo, Italy
    Recent Pat Cardiovasc Drug Discov 2:85-8. 2007
    ....
  31. ncbi Analysis and quantitation of biotinylated apoB-containing lipoproteins with streptavidin-Cy3
    Kaspar Berneis
    Donner Laboratory, Lawrence Berkeley National Laboratory, University of California, Berkeley, CA 94720, USA
    J Lipid Res 43:1155-9. 2002
    ..54 A, P = 0.3). Biotinylation and prestaining of lipoprotein particle with streptavidin-Cy3 provides a new fluorescence-based method for detection and quantitative analysis of lipoprotein subspecies by gradient gel electrophoresis...